Raam S, Robert N, Pappas C A, Tamura H
Department of Medicine, Tufts University School of Medicine, Boston, MA 02111.
J Natl Cancer Inst. 1988 Jul 20;80(10):756-61. doi: 10.1093/jnci/80.10.756.
Neither estrogen dependence nor clinical response to hormone therapy of the tumor is guaranteed by the mere presence of receptors for estrogens (ERs) or progesterones (PRs). Immunohistochemical staining of ER with polyclonal anti-ER antibodies after in vitro transformation has enabled the identification of two types of defective ER among human breast cancers: those that are unable to bind to the nucleus in a hormone-filled state and those that bind to the nucleus as naked ER. Preliminary clinical correlation studies demonstrate that a subclassification of ER(+) tumors based on functional abnormalities of ER may predict refractoriness to hormone therapy.
仅仅存在雌激素受体（ERs）或孕激素受体（PRs）并不能保证肿瘤对雌激素有依赖性或对激素治疗有临床反应。体外转化后用多克隆抗ER抗体对ER进行免疫组织化学染色，已能够在人类乳腺癌中识别出两种类型的缺陷性ER：一种在充满激素的状态下无法与细胞核结合，另一种以无配体的ER形式与细胞核结合。初步的临床相关性研究表明，基于ER功能异常对ER(+)肿瘤进行亚分类可能预测对激素治疗的难治性。
